GlassScriptPhysician profile
Amit Kulkarni
NPI 1417374406
$40,399.81
in general payments reported to CMS, 2019-2025
14 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $39.96 · 2022: $3,533 · 2023: $5,738 · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $2,810 · Consulting Fee: $1,568 · Food and Beverage: $1,366 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,939.55 |
| Travel and Lodging | $2,809.87 |
| Consulting Fee | $1,568.00 |
| Food and Beverage | $1,366.23 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $32,730.04 | 2023-2025 | Libtayo |
| Exelixis INC. | $5,108.21 | 2022-2023 | Cabometyx |
| Genentech USA, INC. | $1,830.00 | 2022 | |
| Steris Corporation | $406.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Janssen Biotech, INC. | $41.74 | 2025 | Rybrevant |
| Chiesi USA, INC. | $39.96 | 2020 | |
| Merck Sharp & Dohme LLC | $35.56 | 2022-2024 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $31.96 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $22.34 | 2022 | |
| Tempus Ai, INC | $14.69 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2023 | Gilotrif |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.